Key Nano-Strategies for Cisplatin Resistance in Advancing Anti-Cancer Therapy

Area of Science:

• Oncology
• Nanomedicine
• Drug Resistance

Background:

• Cisplatin (CDDP) is a vital chemotherapy agent, but drug resistance limits its effectiveness.
• CDDP resistance mechanisms are diverse and heterogeneous, complicating treatment across patients and tumor types.
• Resistance to platinum-based drugs is a shared challenge in cancer therapy.

Purpose of the Study:

• To review innovative nanotechnology-based drug delivery systems (NDDSs) for overcoming CDDP resistance.
• To explore how NDDSs can address pre-target, on-target, off-target, and post-target resistance mechanisms.
• To provide a perspective on NDDS development within a precision medicine framework for cancer therapy.

Main Methods:

• Comprehensive review of current literature on NDDSs and CDDP resistance.
• Analysis of NDDS strategies targeting specific resistance mechanisms.
• Synthesis of advancements in nanotechnology and precision medicine for overcoming platinum resistance.

Main Results:

• NDDSs can act as multifunctional vectors for co-delivering CDDP and resistance modulators.
• Intelligent NDDS platforms enable precise targeting and circumvention of resistance.
• NDDSs hold potential for personalized therapeutic strategies against platinum resistance.

Conclusions:

• NDDSs represent a significant advancement in overcoming CDDP resistance.
• Integrating nanotechnology with precision medicine offers a powerful approach to enhance anti-cancer efficacy.
• Further development of NDDSs is crucial for addressing the persistent challenge of platinum resistance.